Cantex Pharmaceuticals
Weston, US
Find your way into Cantex Pharmaceuticals
Cantex Pharmaceuticals is a pharmaceutical company. The website is currently under construction, so no details about its products or focus are available.
Founders & leadership
CB
Claude BertrandExecutive
SG
Stephen G. MarcusinChief Executive OfficerStephen Marcus is a physician and pharmaceutical executive serving as CEO of Cantex Pharmaceuticals, a clinical-stage company developing cancer and neuroinflammatory disease treatments. He previously contributed to the development of multiple drugs including Betaseron and Mavenclad for multiple sclerosis, fludarabine for leukemia, and temozolomide for brain tumors.
NF
Neil FlanzraichExecutive
Board
CA
Christopher A. KroegerBoard director
TC
Todd C. BradyBoard director
Reported raises · per SEC filings
Form D private placements$3.3M disclosed across 1 round · 2013
▶$3.3MraisedApr 2014 · 7 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedApr 2014 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Claude BertrandExecutive Officer
- Stephen G. MarcusExecutive Officer, Director
- Neil FlanzraichExecutive Officer, Director
- Christopher A. KroegerDirector
- Todd C. BradyDirector
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Feb 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Cantex Pharmaceuticals do?
- Cantex Pharmaceuticals is a pharmaceutical company. The website is currently under construction, so no details about its products or focus are available.
- How much funding has Cantex Pharmaceuticals raised?
- Cantex Pharmaceuticals has disclosed $3.3M raised across 1 round.
- Where is Cantex Pharmaceuticals headquartered?
- Cantex Pharmaceuticals is headquartered in Weston, US.